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Summary 
Polymorphonuclear leukocytes (PMN) have been identified as cells capable of producing a number 
of pro- and antiinflammatory cytokines in response to specific agonists. Previously, we showed 
that tumor necrosis factor (TNF), interleukin-lB (IL-I~, and IL-8, are produced by PMN after 
stimulation with agonists, such as lipopolysaccharide (LPS). In this study, we demonstrate that 
LPS is also a potent stimulus for the mRNA expression and release of the IL-1 receptor antagonist 
(IL-lra). In addition, we show that the release of IL-lra from LPS-stimulated PMN is markedly 
potentiated in the presence of IL-10 (from two to threefold after 18 h of stimulation). Moreover, 
we observed that this upregulation of IL-lra production by IL-10 in LPS-stimulated PMN took 
place through IL-lra mRNA stabilization. Indeed, the half-life of IL-lra mRNA was prolonged 
in PMN stimulated in the presence of IL-10 and LPS,  as compared with cells stimulated with 
LPS alone. That IL-10 selectively upregulates IL-lra production in LPS-activated PMN, while 
it inhibits the production of IL-13, TNF, and IL-8 under the same conditions, suggests that 
IL-10 may be an important physiologic regulator of cytokine production from PMN, and emphasizes 
the potential role of IL-IO in inflammatory responses. 
p MN are specialized effector cells involved in acute inflam- 
matory  responses.  For  instance,  PMN  mediate  an- 
timicrobial defense and antitumoral activity through the re- 
lease of toxic oxygen intermediates or lytic enzymes (1). In 
addition, several studies have shown that PMN have the ability 
to produce many different cytokines known to play an im- 
portant role in inflammatory and immune responses, including 
TNF, IL-1, and IL-8 (reviewed in reference 2). More recently, 
it has been reported that the gene expression and production 
of the IL-1 receptor antagonist (IL-lra) can be stimulated in 
human neutrophils (3-5). IL-lra is a 23- to 25-kD glycosylated 
protein, originally purified from supernatants of human mono- 
cytes cultured on immune complex-coated surfaces  (6), or 
from the urine of patients with monocytic leukemia (7), which 
has been recently cloned (8, 9). While IL-lra competes with 
both IL-lot and IL-13 for binding to the IL-1 receptor (7), 
it does not initiate internalization of the receptor-ligand com- 
plex,  or transduce an activation signal (10). 
Although IL-lra has generated considerable interest based 
on its ability to block the proinflammatory activities of IL-1 
in vivo (11, 12), the regulation of IL-lra expression in human 
PMN remains poorly understood.  Since IL-10, a molecule 
known for its immunosuppressive properties (13), was pre- 
viously shown to modulate TNF, IL-13, and IL-8 cytokine 
gene expression and production in PMN (14), we examined 
the effect of IL-10 on neutrophil-derived IL-lra release. We 
now report that in human PMN, the release of IL-lra was 
potently induced by LPS,  and that IL-10 significantly up- 
regulated LPS-elicited IL-lra production. These findings sug- 
gest that IL-10, by favoring the production of IL-lra by PMN 
over that of IL-1 (14),  may exert potent antiinflammatory 
effects on host responses to gram-negative infections. 
Materials and Methods 
Cell Purification and Culture.  Highly purified (>99.5%)  PMN 
were isolated under endotoxin-free conditions from buffy coats of 
healthy donors, as previously described (14, 15). Immediately after 
purification, PMN were suspended in RPMI 1640 medium sup- 
plemented with 10% low endotoxin FCS (<0.006 ng/ml; Irvine 
Scientific, Santa Ana, CA), in the presence or absence of purified 
recombinant human IL-10 (protein concentration, 50 #g/ml; sp act, 
2  x  107 U/mg; kindly provided by Dr. K. Moore, DNAX and 
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stimulated with  1/~g/ml LPS (from Escherichia coli 026:B6,  pur- 
chased from Sigma Chemical Co.,  St.  Louis,  MO) and cultured 
at 37~  either in 24-well tissue culture plates (Nunc,  Roskilde, 
Denmark)  at  106 cells/300/~1,  or in polystyrene flasks  (Greiner, 
Nurtingen,  Germany) at  5 x 106 cells/ml (14).  Cell-free superna- 
tants were harvested at various time points, spun at 2,000 rpm for 
30 s, and stored at -  70~  before IL-lra determination. All reagents 
were of highest  grade and  were dissolved in pyrogen-free water 
for clinical  use (15). 
RNA  Isolation and Northern Blot  Analyses.  Extraction  and 
Northern blot analysis of total RNA from PMN were performed 
as already described  (14, 15). The cDNA fragment for ILlra (which 
was a gift from Dr. A. Mantovani, Mario Negri Institute, Milano, 
Italy), as well as the cDNA fragments for ILS, IL-1/~, heavy chain 
subunit  of cytochrome  bsss (gp91-phox),  and  actin,  were  32p. 
labeled using a Ready-to-go DNA labeling kit  (Pharmacia LKB, 
Uppsala, Sweden), before hybridization of nylon filters and autora- 
diography. 
Detection oflL-lra.  Extracellular ILlra was determined using 
a  specific  ELISA kit  (50 pg/ml detection  limit)  purchased from 
Amersham International  (Little Chalfort,  UK). 
Statistical Analyses.  Where mentioned,  data were assessed for 
statistical significance  using Student's t test for paired data. Data 
are expressed as means  +  SEM. 
Results 
Effect of  lL-lO on IL-lra Production in LPS-stimulated PMN. 
Purified populations of PMN were preincubated for 30 min 
with optimal doses of IL-10 (100  U/ml)  (14),  and cultured 
for up to 18 h in the presence or absence of LPS. Fig.  1 shows 
that  the  release of IL-lra protein  into  the culture  superna- 
tants of unstimulated PMN (4, 5) was not significantly affected 
by the presence of IL-10. In contrast, PMN stimulation with 
LPS  resulted  in  a  substantial  release of IL-lra protein  that 
began as early as after 2  h  and increased progressively with 
time (Fig.  1). Moreover, IL-10 treatment greatly potentiated 
the secretion of IL-lra protein in LPS-stimulated PMN (Fig. 
1).  This  enhancing  effect of IL-10 was significant  after 6  h 
of LPS stimulation,  and  a maximal effect of IL-10 was ob- 
served at 18 h. Similar results were obtained when PMN were 
exposed  to  as  little  as  10  ng/ml  LPS  (not  shown). 
Effect of  lL-lO on IL-Ira mRNA Expression  in PMN Stimu- 
lated with LPS.  We next determined whether IL-10 exerted 
its enhancing  effect on LPS-stimulated  IL-lra release at the 
level of mRNA.  Northern blot analyses were performed on 
total RNA isolated from PMN preincubated with IL-10, and 
stimulated for different times in the presence or the absence 
of LPS. As shown in Fig. 2, resting PMN expressed low levels 
of IL-lra transcripts, which were not influenced by the pres- 
ence of IL-IO.  Stimulation  of PMN with LPS increased the 
mRNA  steady-state levels of IL-lra, as well as those of IL-8 
and  of  NADPH  oxidase  component  gp91-phox  (16),  in 
keeping  with  previous  observations  (4,  14,  15).  The  LPS- 
induced increase in IL-lra mRNA  steady-state levels was time 
dependent, peaked at 1.5-2 h, and gradually returned to near- 
baseline levels by 20 h  (not  shown).  Pretreatment  of PMN 
with IL-IO had no significant effect on the LPS-elicited en- 
hancement of IL-lra, IL-8, and gp91-phox mRNA  accumu- 
Figure 1.  Effect  of Ibl0 on LPS-induced release of IL-lra from PMN. 
PMN (106/300/~1) were preincubated for 30 min with or without 100 
U/ml IL-10, and then cultured for up to 18 h after the addition of LPS. 
Released IL-lra in the cell-free supernatants were measured by ELISA. A 
shows the mean values •  SEM of duplicate assays for each time point, 
obtained from four experiments performed under the same conditions. 
B shows the mean values _+  SEM of the percentage of enhancement of 
LPS-induced IL-lra release  determined by IL-10. Percent values were calcu- 
lated from the difference in the amount of cytokine produced in the ab- 
sence and presence of ILl0. The values of the constitutive cytokine secre- 
tion were not  subtracted. The asterisks represent significant differences 
between IL-10-treated and untreated PMN.  *p <0.01. 
lation after 2 h. At later time points,  however, the amounts 
of IL-lra mRNA  transcripts were maintained at high levels 
in IL-10-treated PMN,  whereas under the same conditions, 
the LPS-induced accumulation of IL-8 mRNA was suppressed 
by IL-10 pretreatment (14), while that ofgp91-phox mRNA 
was  not  influenced  by the  cytokine  (Fig.  2). 
IL-IO Decreases Turnover of Message for IL-lra,  but not that 
oflL-l~.  In an attempt to elucidate the mechanism whereby 
Figure 2.  Effect  oflbl0 on the 
modulation of neutrophil IL-lra, 
IL8, and gp91-phox gene expres- 
sion induced by LPS. PMN were 
preincubated  with  or  without 
IL-IO for 15 min before addition 
of LPS for the times indicated. 
Total RNA was extracted  and ana- 
lyzed by Northern  analysis. The 
figure shows one experiment rep- 
resentative of four, with similar 
results. 
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LPS-treated PMN, we examined the influence of IL-10 on 
cytokine mRNA stability. PMN were stimulated with LPS 
for 3.5 h, in the presence or absence of IL-10, and then treated 
with actinomycin D to block the formation of additional tran- 
scripts.  At increasing intervals thereafter, the cultures were 
processed  for  Northern blot  analysis,  and changes  in  the 
amount of cytokine mRNA were quantitated by laser den- 
sitometric scanning. Whereas preliminary experiments had 
established  that LPS stimulation (3 h) does not significantly 
alter IL-lra and IL-13 mRNA stability (not shown), Fig. 
3 shows that IL-IO pretreatment markedly prolonged IL-lra 
mRNA half-life relative to diluent-treated cells, after 3.5 h 
of LPS stimulation (180 vs. 54 min, respectively).  A similar 
effect of IL-10 on the turnover rate of IL-lra transcripts was 
exerted in cells stimulated with LPS for 5 h, a time point 
at which the differences in IL-lra mRNA levels were more 
evident (not shown). IL-10 did not significantly affect the 
stability of IL-I~ and actin mRNAs isolated from LPS-treated 
PMN  (Fig.  3). 
Discussion 
IL-1 is widely viewed as an important proinflammatory 
mediator and is thought to play a crucial role in a number 
of pathophysiological conditions (17). The actions of IL-1 
can be controlled in several ways, such as by the regulation 
of its synthesis (18), by the release of soluble IL-1 receptors 
(19, 20), or by the production of IL-lra, an antagonistic in- 
hibitor that blocks IL-1 binding to its receptor (6, 7), thereby 
effectively preventing the biological actions of IL-1 (17). To 
date, studies addressing the expression of IL-lra in human 
PMN remain scarce. It has been reported, for instance, that 
the expression of IL-lra occurred only after neutrophil treat- 
ment with GM-CSF or TNF, but not with LPS, even if  used 
over a 24-h period and at concentrations ranging from sub- 
to superoptimal levels (5). In contrast, other investigators have 
found that PMN have the ability to express IL-lra mRNA 
and protein in response to LPS (100/xg/ml) (4). In the same 
study, it was also demonstrated that, after intratracheal in- 
jection of LPS in the rat, substantial amounts of IL-lra mRNA 
were present in PMN-rich bronchoalveolar lavage (4). More 
recently, Re et al. (21) showed that concentrations of 1-10 
ng/ml LPS were suf~cient to induce IL-lra expression in PMN. 
Our data are therefore consistent with the findings of the 
latter two reports, as well as with preliminary observations 
form our laboratory, that indicate that LPS represents an im- 
portant stimulus for the expression  of IL-lra in PMN, as it 
is more potent than IgG-opsonized yeast particles, or TNF-o~ 
(Cassatella,  M.  A., unpublished observations). 
IL-IO is a product of various cell types including mono- 
cytes  and lymphocytes (13), that potently inhibits mono- 
cyte/macrophage function including proinflammatory  cytokine 
release, oxidative burst, and nitric oxide production (22-24), 
and that contributes to the regulation of  lymphocyte  prolifer- 
ation and differentiation (13). We have recently demonstrated 
that IL-10 can also act upon PMN function by specifically 
suppressing  the LPS-induced release of TNF-ol, IL-13, and 
IL-8 by LPS-stimulated neutrophils (14). In the present re- 
port we show that IL-10 markedly enhances the production 
of IL-lra in PMN stimulated with LPS. Further investiga- 
tion of this effect of IL-10 revealed that whereas the cytokine 
substantially increased  the half-life  of IL-lra transcripts,  it 
failed to modulate IL-13 mRNA stability, thereby demon- 
strating that the posttranscriptional actions of IL-10 are re- 
stricted to selected, LPS-inducible cytokine mRNA species. 
Consistent with our findings, it has been recently reported 
that the suppression by IL-10 of TNF and IL-1 mRNA ac- 
cumulation in LPS-stimulated murine macrophages depended 
on de novo protein synthesis, and was not attributable to 
inhibition of TNF or IL-1 gene transcription rate (25), a con- 
clusion that supports an action of IL-IO on posttranscrip- 
tional events. Although many cytokine mRNA species (e.g., 
TNF, IL-13, IL-8) contain all AU-rich sequences in their Y- 
untranslated regions that are believed  to be involved in the 
regulation of mRNA stability (26), these AU-rich motifs are 
Figure 3.  Effect  of IL-10 on the turnover rate of 
IL-lra and 1I:1/3 mRNAs in LPS-stimulated  PMN. 
PMN were cultured with 1/~g/ml LPS, in the pres- 
ence or absence of IL-10. After 3.5 h, the cells were 
treated with actinomycin  D (5/zg/ml) for an addi- 
tional 4 h. (A) PMN were harvested  at the indicated 
times, and total RNA was prepared and analyzed  by 
Northern blotting  using  IL-lra,  IL-13, and actin  cDNA 
probes. (B) RNA bands were analyzed  densitometri- 
cally,  the data  were  plotted  on semilogarithmic  graphs 
as percent remaining  mR.NA vs. time decays  in min, 
and the resulting values plotted against time. Half- 
lives were calculated  by regression analysis.  One rep- 
resentative  experiment  out of  four  performed  is shown. 
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IL-lra mRNA stability may be regulated by IL-10 in a unique 
manner. It is, for example,  possible that IL-10 reduces the 
expression  of a  nuclease  that  selectively  degrades  IL-lra 
mRNA, or that induces/increases the expression  of a factor 
that decreases the susceptibility of IL-lra mRNA to the ac- 
tion of such a nuclease.  In this respect,  Bogdan et al.  (25) 
postulated the possible existence of nucleolytic activities con- 
trolling TNF and IL-1 mRNA expression, which IL-10 could 
modulate. In any case, other effects of IL-10 at the level of 
PMN transcription, translation or secretion cannot be ex- 
cluded. 
The ability of IL-10 to upregulate IL-lra production in 
PMN may reflect one of the mechanisms underlying the im- 
munosuppressive  actions of IL-10 (13), and in particular could 
contribute to the ef~cacy of IL-10 in downregulating LPS 
toxicity in vivo (27, 28). Very recently, mouse mutants were 
generated in which the IL-10 gene was inactivated by tar- 
geted mutation (29). As these IL-10-deficient mice suffered 
predominantly from chronic enterocolitis (29),  it was pro- 
posed that their primary defect was a failure to control normal 
intestinal immune responses against undefined enteric antigens, 
which led to an overproduction of proinflammatory  cytokines, 
presumably by macrophages (29). On the basis of the present 
data, and of our previous study (14), it appears that one of 
the net effects of IL-10  toward neutrophils is to neutralize 
IL-1, both by inhibiting IL-1 production and by promoting 
the synthesis and secretion of its antagonist. Considering that 
in their initial phases, bowel inflammation diseases are also 
characterized by a massive infiltration of neutrophils (30), 
the importance of the PMN as a source of cytokines under 
those circumstances must not be underestimated. 
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